Company Overview of Pelias Biomedizinische Entwicklungs AG
Pelias Biomedizinische Entwicklungs AG, a biotechnology company, develops treatments against hospital-acquired infections. The company’s programs include preventive and therapeutic vaccines, as well as therapeutic antibodies targeting common pathogens that cause serious or life-threatening infections acquired during hospitalization. It focuses on pathogens causing hospital-acquired infections, such as Pseudomonas, Klebsiella, and Enterococcus. The company was founded in 2005 and is based in Vienna, Austria. As of January 2, 2007, Pelias Biomedizinische Entwicklungs AG is a subsidiary of Intercell Biomedical Research & Development AG.
Founded in 2005
43 1 718 03 26
43 1 718 03 26 - 800
Key Executives for Pelias Biomedizinische Entwicklungs AG
Similar Private Companies By Industry
|Activartis Biotech GmbH||Europe|
|APEIRON Biologics AG||Europe|
|Apeptico Forschung und Entwicklung GmbH||Europe|
|ARTMA Medical Technologies AG||Europe|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|The Advertising Council, Inc.||United States|
|NYC2012, Inc.||United States|
|Tax Management Inc||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Pelias Biomedizinische Entwicklungs AG, please visit www.pelias.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.